within Pharmacolibrary.Drugs.ATC.L;

model L04AA24
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 700 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0060999999999999995,
    k12             = 0.202,
    k21             = 0.202
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AA24</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Abatacept is a selective T-cell co-stimulation modulator used for the treatment of moderate to severe rheumatoid arthritis and other autoimmune diseases. It is a fusion protein composed of the extracellular domain of human cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) linked to the modified Fc portion of human IgG1. Abatacept is approved and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult rheumatoid arthritis patients following intravenous administration at a dose of ~10 mg/kg; parameter values represent commonly reported population means.</p><h4>References</h4><ol><li><p>Li, X, et al., &amp; Murthy, B (2019). Population Pharmacokinetics and Exposure-Response Relationship of Intravenous and Subcutaneous Abatacept in Patients With Rheumatoid Arthritis. <i>Journal of clinical pharmacology</i> 59(2) 245–257. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1308&quot;>10.1002/jcph.1308</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30229926/&quot;>https://pubmed.ncbi.nlm.nih.gov/30229926</a></p></li><li><p>Balevic, SJ, et al., &amp; Hornik, CP (2024). Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical Trial. <i>JAMA network open</i> 7(4) e247615–None. DOI:<a href=&quot;https://doi.org/10.1001/jamanetworkopen.2024.7615&quot;>10.1001/jamanetworkopen.2024.7615</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38662372/&quot;>https://pubmed.ncbi.nlm.nih.gov/38662372</a></p></li><li><p>Hervey, PS, &amp; Keam, SJ (2006). Abatacept. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 20(1) 53–62. DOI:<a href=&quot;https://doi.org/10.2165/00063030-200620010-00004&quot;>10.2165/00063030-200620010-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16573350/&quot;>https://pubmed.ncbi.nlm.nih.gov/16573350</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AA24;
